TLDR
- Many peptides act as ligands, molecules that bind selectively to receptors on or within cells.
- Receptor binding depends on the peptide’s amino acid sequence, shape, charge, hydrophobicity, and chemical modifications.
- G protein-coupled receptors, or GPCRs, are major targets for peptide hormones and neuropeptides, but they are not the only receptors that recognize peptides.
- Binding and receptor activation are different concepts. A peptide may bind tightly without strongly activating a receptor.
- Affinity, potency, efficacy, selectivity, and binding kinetics describe different aspects of peptide-receptor interactions.
- Modern receptor research combines binding assays, functional assays, structural biology, and computational methods to understand what a peptide actually does.
A peptide can contain only a few dozen amino acids and still trigger a complex series of events inside a cell.
The first step is often deceptively simple: the peptide binds to a receptor.
But understanding how peptides interact with receptors requires more than the familiar “lock and key” analogy. Receptors are dynamic proteins. Peptides are often flexible molecules. Both can change conformation during binding, and a single receptor can sometimes produce different intracellular signals depending on which ligand activates it.
Those details are central to modern peptide research.
What Is a Receptor?
A receptor is a molecule, usually a protein, that recognizes particular chemical signals and converts that interaction into a biological response.
The molecule that binds the receptor is called a ligand.
A ligand can be:
- a peptide
- a protein
- a lipid
- a neurotransmitter
- a hormone
- an ion
- a small organic molecule
- another signaling molecule
Peptide ligands include many hormones, neuropeptides, chemokines, and regulatory molecules.
Receptors allow cells to respond selectively to those signals.
That selectivity is important because cells are surrounded by thousands of molecules at any given time. A receptor must distinguish relevant signals from the rest of the chemical environment.
How Peptides Interact With Receptors
Peptide-receptor binding depends on complementary molecular interactions.
A peptide does not usually attach to a receptor through one single bond. Instead, multiple weak interactions collectively stabilize the ligand-receptor complex.
These can include:
- hydrogen bonds
- electrostatic interactions
- hydrophobic interactions
- van der Waals forces
- ionic or salt-bridge interactions
Different amino acid side chains contribute different chemical properties.
A positively charged lysine or arginine residue, for example, can interact with negatively charged groups on a receptor. Hydrophobic amino acids may fit into nonpolar pockets. Aromatic residues can contribute additional hydrophobic or stacking interactions.
The exact three-dimensional arrangement matters.
Modern structural studies show that peptide ligands can make extensive and highly specific contacts with extracellular receptor regions and deeper receptor binding pockets.
Why “Lock and Key” Is Only Part of the Story
The lock-and-key analogy is useful for introducing receptor binding, but real peptide-receptor interactions are more dynamic.
Neither the peptide nor the receptor necessarily behaves as a rigid object.
Peptides can exist as ensembles of different conformations in solution. Receptors also shift among different structural states.
Binding can favor particular conformations.
In some cases, the ligand appears to select a receptor conformation that already exists within a dynamic population. In other situations, ligand binding promotes additional structural rearrangement.
The result is better described as molecular recognition between flexible structures.
This concept becomes especially important when considering receptor activation.
Two peptides can bind the same receptor but stabilize different receptor conformations. Those differences can affect what happens inside the cell.
G Protein-Coupled Receptors Are Major Peptide Receptors
A large amount of peptide signaling occurs through G protein-coupled receptors, usually abbreviated GPCRs.
GPCRs have a characteristic structure containing seven membrane-spanning alpha helices.
The human genome contains more than 800 GPCRs. The family responds to an extremely broad range of signals, including peptides, lipids, amines, odorants, photons, nucleotides, and other molecules.
Peptide-responsive GPCRs regulate processes involving:
- metabolism
- cardiovascular function
- appetite and energy balance
- pain
- reproduction
- neurological signaling
- endocrine regulation
- immune activity
Peptide ligands studied in GPCR biology include angiotensin II, glucagon, GLP-1, parathyroid hormone, opioid peptides, chemokines, neurotensin, and many others.
A major 2026 Nature Reviews Methods Primers article describes peptide-GPCR research as a field increasingly combining structural biology, functional pharmacology, peptide libraries, computational modeling, and AI-assisted peptide design.
How a Peptide Activates a GPCR
A simplified GPCR signaling sequence looks like this:
Peptide binds receptor → receptor changes conformation → intracellular signaling protein engages → second-messenger pathway changes → cellular response occurs
The details vary substantially between receptors.
One common structural feature of GPCR activation is movement within the receptor’s transmembrane helices.
In many GPCRs, agonist binding promotes structural rearrangements that cause part of transmembrane helix 6 to move outward on the intracellular side.
That creates space for a G protein to interact with the activated receptor.
The receptor can then influence different types of heterotrimeric G proteins.
Important families include:
- Gs
- Gi/o
- Gq/11
- G12/13
These G proteins control different intracellular pathways.
For example, Gs signaling commonly increases activity of adenylyl cyclase and raises cyclic AMP, or cAMP.
Gi commonly reduces adenylyl cyclase activity.
Gq can activate phospholipase C, leading to changes in intracellular calcium and other signaling molecules.
This means receptor activation is not itself the final biological effect. It is the start of a signaling network.
Class A and Class B Peptide GPCRs Can Bind Differently
Not every peptide-binding GPCR recognizes its ligand in the same way.
Structural research has revealed major differences between receptor families.
Class A Peptide GPCRs
Class A is the largest GPCR family.
Some peptide ligands interact with extracellular loops and then extend into a binding pocket formed by the transmembrane helices.
The depth and orientation of peptide binding varies considerably among receptors.
Certain peptides insert an important terminal amino acid deep into the receptor. That interaction can help trigger the conformational changes associated with receptor activation.
Class B Peptide GPCRs
Class B GPCRs include receptors for several larger peptide hormones.
These receptors have a relatively large extracellular domain.
A widely used model for class B peptide binding involves two regions of interaction.
The C-terminal portion of the peptide interacts with the receptor’s extracellular domain, helping establish binding and orientation.
The peptide’s N-terminal region then interacts with the transmembrane receptor core and contributes strongly to activation.
Structural studies of receptors such as GLP-1R and PTH1R support this general two-domain model, although individual interactions vary by receptor and ligand.
This is a good example of why small sequence changes can matter. One region of a peptide may contribute strongly to binding, while another is especially important for activating the receptor.
Not All Peptide Receptors Are GPCRs
GPCRs receive a lot of attention in peptide research, but peptides communicate through several other receptor families.
Receptor Tyrosine Kinases
Insulin provides a major example.
The insulin receptor is a receptor tyrosine kinase, not a GPCR.
Insulin binding produces structural changes in the receptor that promote tyrosine phosphorylation of the receptor and downstream proteins.
Major pathways activated downstream include PI3K-AKT signaling and other kinase networks involved in metabolism, growth, and cellular regulation.
Receptor Guanylyl Cyclases
Natriuretic peptides use another mechanism.
Atrial natriuretic peptide, or ANP, and B-type natriuretic peptide, or BNP, can activate the receptor guanylyl cyclase known as GC-A or NPR-A.
This receptor contains an extracellular peptide-binding domain, a single membrane-spanning region, and an intracellular guanylyl cyclase domain.
Ligand activation increases production of cyclic GMP, or cGMP, which then regulates downstream signaling.
These examples make an important point:
Peptide is a description of the ligand. It does not specify the type of receptor or signaling pathway that ligand will use.
What Is Receptor Affinity?
Affinity describes how strongly a ligand tends to bind to its receptor under defined conditions.
One commonly used measurement is the equilibrium dissociation constant, Kd.
For a simple ligand-receptor system, a lower Kd indicates higher affinity.
Conceptually:
- lower Kd = tighter binding
- higher Kd = weaker binding
Under the assumptions of a simple equilibrium binding model, the Kd corresponds to the free ligand concentration at which approximately half of the available receptors are occupied.
But this needs context.
Real receptor systems may be more complicated than a one-site equilibrium model.
Receptors can:
- exist in multiple conformations
- interact with other proteins
- form dimers or larger complexes
- undergo internalization
- bind ligands at more than one site
- change affinity depending on cellular conditions
So Kd is a useful experimental parameter, not a universal property that exists independently of the experimental system.
Affinity and Potency Are Not the Same Thing
These terms are often confused.
Affinity concerns ligand binding.
Potency concerns how much ligand is required to produce a measured biological response in a particular assay.
Potency is commonly summarized using values such as EC50, the concentration producing half of the maximal measured response.
A peptide with high receptor affinity is not automatically the most potent peptide in every functional assay.
Potency can be affected by:
- receptor density
- signaling amplification
- receptor reserve
- ligand stability
- binding kinetics
- assay duration
- cell type
- downstream signaling proteins
- the response being measured
The same peptide can therefore produce different EC50 values in different experimental systems.
What Is Efficacy?
Efficacy describes the ability of a ligand, once bound, to produce receptor activation and a biological response.
This separates another pair of concepts:
Does the peptide bind?
and
What does the receptor do after it binds?
Those are different questions.
A ligand may bind with high affinity but produce little or no receptor activation.
This is one reason receptor research generally requires both binding and functional experiments.
Agonists, Partial Agonists, Antagonists, and Inverse Agonists
Pharmacologists use several terms to describe how receptor ligands affect receptor activity.
Agonist
An agonist binds to a receptor and promotes a receptor state that produces a biological response.
IUPHAR defines an agonist as a ligand that binds a receptor and alters receptor state in a way that results in a response.
Partial Agonist
A partial agonist activates a receptor but produces a lower maximal response than a full agonist under the same experimental conditions.
That does not necessarily mean it binds weakly.
A partial agonist can have high affinity but lower efficacy.
Antagonist
A receptor antagonist reduces or prevents the action of an agonist without producing the same activating response itself.
A competitive antagonist often binds the same general receptor site used by the agonist.
Other forms of antagonism are possible.
Inverse Agonist
Some receptors have measurable activity even without an agonist present.
This is called constitutive activity.
An inverse agonist reduces that basal receptor activity.
These categories describe pharmacological behavior. They should not be inferred simply from a peptide’s sequence.
What Is an Orthosteric Binding Site?
The orthosteric site is the primary receptor site used by the endogenous ligand.
For a receptor naturally activated by a peptide hormone, that hormone typically occupies the orthosteric binding region.
An allosteric site is a different location on the receptor.
A molecule binding an allosteric site may alter:
- ligand affinity
- receptor activation
- signaling efficacy
- binding kinetics
Allosteric regulation is an active area of receptor pharmacology because it can potentially change receptor behavior without simply reproducing or blocking the endogenous ligand interaction.
Receptor Selectivity Is Not Absolute
A peptide may bind one receptor much more strongly than another. This is described as selectivity.
Sequence differences among related receptors create different binding environments.
Likewise, changing one or several amino acids within a peptide can alter which receptors it recognizes.
Researchers often study these relationships using structure-activity relationships, or SAR.
A typical SAR experiment might:
- begin with an active peptide;
- replace one amino acid;
- measure receptor binding;
- measure receptor activation;
- compare the result with the original peptide.
Repeating this process can identify residues that are especially important for affinity, efficacy, or selectivity.
But selectivity is relative.
Calling a peptide “selective” does not necessarily mean it interacts with only one receptor under every possible condition.
The concentration being tested matters.
Binding Kinetics Add Another Layer
Equilibrium affinity is not the whole story.
Researchers can also measure how quickly a peptide binds and leaves a receptor.
Two important quantities are:
kon: association rate
koff: dissociation rate
A ligand that dissociates slowly has a longer residence time on the receptor.
Two ligands can have similar equilibrium affinity while having quite different association and dissociation kinetics.
That difference can influence the timing and duration of receptor occupancy.
It can also complicate experiments if equilibrium has not actually been reached.
One Receptor Can Produce More Than One Signal
The old view of receptor signaling was relatively simple.
Ligand A binds receptor A, which turns pathway A on.
Modern receptor biology is much more complicated.
GPCRs in particular can interact with several signaling partners.
A receptor may activate one or more G protein pathways and also interact with proteins such as beta-arrestins.
Different ligands can stabilize different receptor conformations, potentially favoring one signaling pathway over another.
This phenomenon is often described as biased agonism or functional selectivity.
There is strong structural and experimental support for ligand-dependent signaling bias, but interpreting it requires care. Apparent bias can also depend on receptor expression, assay amplification, cell type, timing, and the specific signaling endpoints being measured.
So saying that a peptide is “biased” without specifying the experimental system provides incomplete information.
Receptors Can Become Desensitized
Cells also regulate how strongly they respond to persistent signals.
After GPCR activation, receptors may become phosphorylated.
Beta-arrestins can then interact with some activated receptors, reducing further G protein coupling and promoting receptor internalization.
The receptor may later:
- return to the cell surface
- remain inside the cell
- continue signaling from an intracellular location
- be directed toward degradation
This means cellular response depends partly on time.
A five-minute peptide exposure and a several-hour exposure may not produce equivalent signaling patterns.
How Researchers Measure Peptide-Receptor Interactions
No single experiment completely describes a peptide-receptor interaction.
Researchers often combine several types of assays.
Direct Binding Assays
Binding experiments ask whether a ligand physically associates with a receptor.
These can include:
- radioligand binding
- fluorescence-based binding assays
- competition binding assays
- biophysical binding techniques
- modern label-free approaches
Saturation binding experiments can estimate receptor density and equilibrium affinity under defined conditions.
Competition experiments can examine how an unlabeled peptide competes with a known ligand.
Functional Assays
Functional assays ask what happens after receptor engagement.
Depending on the receptor, researchers might measure:
- cAMP
- intracellular calcium
- cGMP
- protein phosphorylation
- beta-arrestin recruitment
- gene transcription
- receptor internalization
A peptide that binds in a biochemical experiment may fail to produce the expected response in a functional assay.
That difference is scientifically meaningful.
Structural Biology
X-ray crystallography and especially cryogenic electron microscopy have dramatically expanded the number of peptide-receptor structures available to researchers.
By 2024, hundreds of peptide-bound GPCR structures had been reported, providing direct views of ligand-receptor contacts and activated receptor conformations.
Computational Methods
Molecular docking, molecular dynamics, sequence analysis, machine learning, and generative design are increasingly used to predict or optimize peptide-receptor interactions.
But computational predictions still need experimental validation.
The 2026 Nature primer on peptide-GPCR discovery specifically identifies assay artifacts, peptide instability, annotation problems, and limitations of computational approaches as continuing challenges.
Why Small Peptide Changes Can Produce Large Effects
Replacing one amino acid may seem minor.
At the molecular level, it can change:
- charge
- hydrogen bonding
- steric fit
- hydrophobicity
- peptide flexibility
- secondary structure
- protease sensitivity
- receptor contacts
Changing the N- or C-terminus can also matter.
So can cyclization, lipidation, amidation, acetylation, and other chemical modifications.
A modified peptide therefore should not automatically be assumed to behave exactly like the natural sequence it resembles.
Its properties need to be measured.
Receptor Activity Does Not Automatically Predict an Effect in an Organism
This is one of the most important principles in peptide research.
Suppose a peptide activates a receptor in cultured cells.
That establishes something useful about that experimental system.
It does not by itself establish what will happen in an intact organism.
Additional factors include:
- peptide degradation
- tissue distribution
- membrane barriers
- metabolism
- clearance
- receptor expression
- off-target interactions
- dose and exposure
- feedback systems
- species differences
An in vitro receptor assay, an animal experiment, and a controlled human study answer different scientific questions.
Mechanistic receptor data are valuable, but they are one part of a much larger evidence chain.
FAQs
Do All Peptides Bind to Receptors?
No. Many biologically active peptides are receptor ligands, but peptides can also interact with enzymes, membranes, proteins, nucleic acids, and other molecular targets.
What Determines Which Receptor a Peptide Binds?
The peptide’s sequence, three-dimensional conformation, charge distribution, hydrophobicity, terminal groups, and other structural features can all contribute to receptor recognition.
Does Stronger Receptor Binding Mean a Stronger Biological Effect?
Not necessarily. Affinity describes binding strength, while efficacy describes receptor activation. Potency also depends on the experimental system and downstream signaling.
What Does Kd Mean?
Kd is the equilibrium dissociation constant. In a simple one-site model, lower Kd values indicate higher affinity.
What Is the Difference Between EC50 and Kd?
Kd is principally a binding parameter. EC50 is a functional parameter describing the concentration required to produce half of the maximal measured response in an assay. They are not interchangeable.
Are All Peptide Receptors GPCRs?
No. Many are GPCRs, but peptide hormones can also signal through receptor tyrosine kinases, receptor guanylyl cyclases, and other receptor systems.
Can Two Peptides Activate the Same Receptor Differently?
Yes. Different ligands can differ in affinity, efficacy, binding kinetics, and signaling pathway preference. GPCR research increasingly investigates this phenomenon through pathway-resolved functional assays.
References
- Kim J, Kim J, Choi C, et al. Structural insights into GPCR signaling activated by peptide ligands: from molecular mechanism to therapeutic application. Experimental & Molecular Medicine. 2025.
- Hermes J, Matic M, Yeung HY, et al. Peptide ligand discovery of G protein-coupled receptors. Nature Reviews Methods Primers. 2026;6:52.
- Tikhonova IG, et al. Understanding Peptide Binding in Class A G Protein-Coupled Receptors. Molecular Pharmacology. 2019.
- NC-IUPHAR. Terms and Symbols in Quantitative Pharmacology. Guide to Pharmacology.
- Sykes DA, et al. Binding kinetics of ligands acting at GPCRs. Molecular and Cellular Endocrinology. 2019.
- Tóth AD, Turu G, Hunyady L. Functional consequences of spatial, temporal and ligand bias of G protein-coupled receptors. Nature Reviews Nephrology. 2024.
- Choi E, Duan C, Bai XC. Regulation and function of insulin and insulin-like growth factor receptor signalling. Nature Reviews Molecular Cell Biology. 2025.
- Yunn NO, Kim J, Ryu SH, et al. A stepwise activation model for the insulin receptor. Experimental & Molecular Medicine. 2023.
- Potter LR. Regulation and therapeutic targeting of peptide-activated receptor guanylyl cyclases. Pharmacology & Therapeutics.
- Ogawa H, et al. Structure, signaling mechanism and regulation of natriuretic peptide receptor-guanylate cyclase. Journal of Biochemistry.